Shah Gautam 4

Accession 0001181431-13-001234

CIK 0001070336other

Filed

Jan 2, 7:00 PM ET

Accepted

Jan 3, 5:42 PM ET

Size

21.0 KB

Accession

0001181431-13-001234

Form 4

Period: 2012-12-31

SVP and Chief Compliance Ofc.

Transactions

Exercise/Conversion
Common Stock
2012-12-31$1.05/sh+14,899$15,644→ 18,024 total
Sale
Common Stock
2013-01-02$8.40/sh−26,965$226,614→ 3,125 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2012-12-31−73,269→ 114,731 total
Exercise: $3.10Exp: 2020-12-16→ Common Stock (73,269 underlying)
Sale
Common Stock
2012-12-31$8.01/sh−88,168$706,093→ 3,125 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2012-12-31−14,899→ 0 total
Exercise: $1.05Exp: 2018-12-15→ Common Stock (14,899 underlying)
Exercise/Conversion
Common Stock
2013-01-02$3.10/sh+20,731$64,266→ 30,090 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2013-01-02−20,731→ 94,000 total
Exercise: $3.10Exp: 2020-12-16→ Common Stock (20,731 underlying)
Exercise/Conversion
Common Stock
2012-12-31$3.10/sh+73,269$227,134→ 91,293 total
Exercise/Conversion
Common Stock
2013-01-02$3.28/sh+6,234$20,448→ 9,359 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2013-01-02−6,234→ 8,313 total
Exercise: $3.28Exp: 2019-12-18→ Common Stock (6,234 underlying)

Footnotes (5)

[F1]This option was granted on December 15, 2008 and vested over a four year period with 25% of the shares vesting on the first anniversary of the date of grant and an additional 6.25% vesting at the end of each three-month period thereafter.
[F2]This option was granted on December 16, 2010 and vests over a four year period with 25% of the shares vesting on the first anniversary of the date of grant and an additional 6.25% vesting at the end of each three-month period thereafter.
[F3]This option was granted on December 18, 2009 and vests over a four year period with 25% of the shares vesting on the first anniversary of the date of grant and an additional 6.25% vesting at the end of each three-month period thereafter.
[F4]The price in column is a weighted average price. The actual sale prices for these transactions ranged from $8.00 to $8.03. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. within the range.
[F5]The price in column is a weighted average price. The actual sale prices for these transactions ranged from $8.30 to $8.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. within the range.

Documents

1 file

ACHILLION PHARMACEUTICALS INC

CIK 0001070336

Entity typeother